Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05045703
Other study ID # Pro00108901
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date May 2023
Est. completion date May 2024

Study information

Verified date June 2023
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Choroideremia (CHM) is an inherited retinal disorder that causes progressive vision loss, ultimately leading to complete blindness. The first symptom is generally night blindness, although, to date, little is known about the extent, type, pattern, and progression of dark-adapted visual function measures in CHM patients. We hypothesize that one of the key events causing night blindness in CHM is deficiency in the chromophore of the rod visual pigment, rhodopsin. We propose that this deficiency is at least in part due to inadequate delivery of vitamin A (all-trans-retinol) to the photoreceptors (PRs) from the ailing retinal pigment epithelium (RPE), characteristic of CHM. We hypothesize that increased availability of vitamin A would potentiate its entry into the RPE-mediated visual cycle, ultimately enabling delivery to the PRs. This would in turn allow rods to perform better by partially overcoming the RPE damage and the impaired chromophore recycling that we postulate exists in CHM. The goals of this proposal are: (1) to test the hypothesis that oral vitamin A supplementation can improve night time and peripheral vision in CHM patients, and (2) to provide detailed characterization of dark-adapted visual function outcome measures to guide interventional CHM trials.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 2024
Est. primary completion date March 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 15 Years and older
Eligibility Inclusion Criteria: - males at least 15 years of age with molecularly-confirmed diagnosis of choroideremia Exclusion Criteria: - inability to participate in visual field testing reliably and reproducibly

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Vitamin A palmitate
Vitamin A palmitate, 15,000 IU daily for 4 months

Locations

Country Name City State
United States Duke Eye Center Durham North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Duke University Foundation Fighting Blindness

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in dark-adapted full-field visual field sensitivity Dark-adapted full-field visual field sensitivity will be measured using the Medmont dark-adapted chromatic perimeter. Measurements at 0, 4, and 8 months. The 0 months measurement will serve as the baseline. The 4 month measurement will assess change due to vitamin A supplementation. The 8 month measurement will assess reversal of this change following washout period
Primary Change in dark-adapted macular visual field sensitivity Dark-adapted macular visual field sensitivity will be measured using the Medmont dark-adapted chromatic perimeter. Measurements at 0, 4, and 8 months. The 0 months measurement will serve as the baseline. The 4 month measurement will assess change due to vitamin A supplementation. The 8 month measurement will assess reversal of this change following washout period
Primary Change in dark adaptometry Dark adaptometry will be measured using the MacuLogix AdaptDx dark adaptometer. Measurements at 0, 4, and 8 months. The 0 months measurement will serve as the baseline. The 4 month measurement will assess change due to vitamin A supplementation. The 8 month measurement will assess reversal of this change following washout period
Secondary Change in best corrected visual acuity Best corrected visual acuity will be measured using the ETDRS chart Measurements at 0, 4, and 8 months. The 0 months measurement will serve as the baseline. The 4 month measurement will assess change due to vitamin A supplementation. The 8 month measurement will assess reversal of this change following washout period
Secondary Change in low luminance visual acuity Low luminance visual acuity will be measured using the ETDRS chart in low luminance conditions Measurements at 0, 4, and 8 months. The 0 months measurement will serve as the baseline. The 4 month measurement will assess change due to vitamin A supplementation. The 8 month measurement will assess reversal of this change following washout period
Secondary Change in full-field light-adapted visual field sensitivity Light-adapted full-field visual field sensitivity will be measured using the Octopus 172-point GATE full-field semi-automated kinetic perimetry (SKP) Measurements at 0, 4, and 8 months. The 0 months measurement will serve as the baseline. The 4 month measurement will assess change due to vitamin A supplementation. The 8 month measurement will assess reversal of this change following washout period
Secondary Change in light-adapted macular visual field sensitivity Light-adapted macular visual field sensitivity will be measured using the Centervue MAIA confocal macular microperimeter Measurements at 0, 4, and 8 months. The 0 months measurement will serve as the baseline. The 4 month measurement will assess change due to vitamin A supplementation. The 8 month measurement will assess reversal of this change following washout period
Secondary Change in retinal pigmented epithelium (RPE) atrophy by optical coherence tomography Retinal pigmented epithelium (RPE) atrophy will be measured using the Spectralis macular spectral domain optical coherence tomography (SD-OCT) with and without enhanced depth imaging (EDI) Measurements at 0, 4, and 8 months. The 0 months measurement will serve as the baseline. The 4 month measurement will assess change due to vitamin A supplementation. The 8 month measurement will assess reversal of this change following washout period
Secondary Change in retinal pigmented epithelium (RPE) atrophy by color photography Retinal pigmented epithelium (RPE) atrophy will be measured using the Optos wide-field color fundus photography (WF-CFP) Measurements at 0, 4, and 8 months. The 0 months measurement will serve as the baseline. The 4 month measurement will assess change due to vitamin A supplementation. The 8 month measurement will assess reversal of this change following washout period
Secondary Change in retinal pigmented epithelium (RPE) atrophy by fundus autofluorescence Retinal pigmented epithelium (RPE) atrophy will be measured using the Optos wide-field fundus auto-fluorescence (WF-FAF) Measurements at 0, 4, and 8 months. The 0 months measurement will serve as the baseline. The 4 month measurement will assess change due to vitamin A supplementation. The 8 month measurement will assess reversal of this change following washout period
Secondary Change in retinal pigmented epithelium (RPE) atrophy by fundoscopy Retinal pigmented epithelium (RPE) atrophy will be assessed by slit lamp biomicroscopy Measurements at 0, 4, and 8 months. The 0 months measurement will serve as the baseline. The 4 month measurement will assess change due to vitamin A supplementation. The 8 month measurement will assess reversal of this change following washout period
Secondary Change in liver function Liver function profile will be measured by laboratory using participant serum samples Measurements at 0, 4, and 8 months
Secondary Change in serum vitamin A levels Serum vitamin A levels will be measured by laboratory using participant serum samples Measurements at 0, 4, and 8 months. The 0 months measurement will serve as the baseline. The 4 month measurement will assess change due to vitamin A supplementation. The 8 month measurement will assess reversal of this change following washout period
See also
  Status Clinical Trial Phase
Completed NCT02553135 - Choroideremia Gene Therapy Clinical Trial Phase 2
Completed NCT01461213 - Gene Therapy for Blindness Caused by Choroideremia Phase 1/Phase 2
Completed NCT03507686 - A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111 Phase 2
Recruiting NCT05258032 - Structural and Functional Characterization of Rare Ocular Diseases
Recruiting NCT05282953 - A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) Phase 1/Phase 2
Recruiting NCT01866371 - High Resolution Retinal Imaging
Completed NCT01603576 - Pilot Study of a Suprachoroidal Retinal Prosthesis N/A
Enrolling by invitation NCT03584165 - Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa Phase 3
Completed NCT03359551 - Natural History of the Progression of Choroideremia Study
Recruiting NCT02435940 - Inherited Retinal Degenerative Disease Registry
Active, not recruiting NCT04483440 - Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia Phase 1
Completed NCT02671539 - THOR - Tübingen Choroideremia Gene Therapy Trial Phase 2
Completed NCT02670980 - Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy N/A
Completed NCT02341807 - Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations Phase 1/Phase 2
Completed NCT03406416 - Study of a Suprachoroidal Retinal Prosthesis N/A
Enrolling by invitation NCT05158049 - Longitudinal Study of a Bionic Eye
Terminated NCT02994368 - "Natural History" Study of Choroideremia
Terminated NCT01654562 - The Short-term Effects of Simvastatin on the Vision of Males Affected by Choroideremia Phase 1/Phase 2
Active, not recruiting NCT00427180 - IRIS PILOT - Extended Pilot Study With a Retinal Implant System N/A
Completed NCT04750785 - A Study to Assess Choroideremia (CHM) Health Outcomes